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Abstract
Background and Objectives There are limited data
examining the real-world use of gabapentin and pregabalin
for the treatment of post-herpetic neuralgia (PHN). This
study examines dosing patterns, therapy outcomes,
healthcare utilization and costs of patients with PHN who
initiate treatment with gabapentin or pregabalin.
Methods This was a retrospective administrative claims
data analysis from July 2005 to February 2010. Patients
with PHN initiating gabapentin or pregabalin (index ther-
apy) from January 2006 to February 2009 were identified
and were observed for 12 months after index therapy ini-
tiation. Outcomes were mean daily dosages of the index
therapy, attainment of minimally effective dosages of
gabapentin (C1,800 mg/day) or pregabalin (C150 and
C300 mg/day) persistence, discontinuation, index therapy
switching, addition of neuropathic pain medications to
index therapy, and healthcare resource use and costs.
Results 1,645 patients were identified. The mean daily
dosage was 826 mg for gabapentin and 187 mg for pre-
gabalin. Only 52.6 % of patients initiating gabapentin and
56.9 % initiating pregabalin obtained a refill during the
post-index period. Approximately 14 % of patients treated
with gabapentin reached the target dosage (1,800 mg/day).
For pregabalin, 87 % reached C150 mg/day and 27 %
reached C300 mg/day. On average, patients took 10 weeks
to reach 1,800 mg/day gabapentin, and 5.0 and 9.2 weeks
to reach C150 mg/day and C300 mg/day pregabalin,
respectively. Approximately one-third of patients in both
index therapy cohorts added a pain medication; more than
half added opioids. The percentage of patients switching
from either drug (57 %) or adding a therapy (34 %) were
similar between index therapy cohorts; opioids were the
most common therapy patients switched to or added.
Conclusion It appears that gabapentin and pregabalin are
not used effectively to treat PHN. Suboptimal dosing and
discontinuation may be associated with supplementary use
of other analgesics, especially opioids.
1 Introduction
Approximately 2–3 % of the US population suffers from
neuropathic pain [1]. A common cause of neuropathic pain is
post-herpetic neuralgia (PHN), a complication of herpes
zoster. PHN may persist for weeks, or years, after the initial
shingles rash has healed [2]. Although studies have demon-
strated that the overall incidence of PHN following acute
zoster is approximately 20 %, the incidences of PHN for
individuals over the age of 50 and 75 years are as high as 40
and 75 %, respectively [3–6]. Because of the acute pain
associated with PHN, quality of life is often negatively
affected. In addition, PHN may interfere with daily activities,
and may lead to insomnia, fatigue, depression and anxiety [7].
Antiepileptic medications and tricyclic antidepressants
have been the mainstay of pharmacological treatment of
neuropathic pain. Gabapentin and pregabalin are the only US
Food and Drug Administration (FDA)-approved antiepilep-
tics indicated for the treatment of neuropathic pain.
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Gabapentin and pregabalin are oral agents that bind to the a2d
subunit of calcium channels in neurons and are believed to
regulate neurotransmitter levels [8]. In two large multicentre
studies, patients with PHN treated with gabapentin experi-
enced significant reductions in pain compared with patients
receiving placebo [9, 10]. Patients on gabapentin also showed
significantly less sleep interference and improvements in
mood [11, 12]. Pregabalin has been shown to be effective and
tolerable in patients treated for neuropathic pain associated
with PHN [13]. The beneficial effect of tricyclic antidepres-
sants (e.g., amitriptyline, nortriptyline) in PHN treatment has
also been demonstrated in several clinical trials [14–17].
This study used a large administrative claims database
from a national US health plan to examine dosing patterns,
therapy outcomes, and healthcare utilization and costs
among patients with PHN treated with gabapentin and
pregabalin. Because both gabapentin and pregabalin must
be titrated to an effective dosage and continued for an
adequate duration to alleviate the pain associated with PHN,
we were interested to determine how many patients with
PHN receive effective dosages of these therapies and how
long they continue them in real-world practice. Further-
more, we examined which additional therapies were added
to gabapentin or pregabalin or to what other therapies
patients switched. Opioid analgesics, which are not first-line
therapies for PHN, are also efficacious [18–20], but second-
line use of them is controversial because of their risk for
potential abuse, concerns regarding their long-term safety,
and side effects such as constipation, nausea and drowsi-
ness. Finally, we examined the costs for patients with PHN
initiating treatment with gabapentin or pregabalin.
2 Methods
2.1 Study Design and Data Source
This was a retrospective claims database study using medical
and pharmacy claims data and enrollment information from a
proprietary claims database affiliated with OptumInsight.
Individuals covered by this health plan, 26.9 million adults
during the study period, were geographically diverse, with
greatest representation in the South and Midwest US census
regions. All study data were accessed using techniques com-
pliant with the Health Insurance Portability and Account-
ability Act of 1996, and no identifiable protected health
information was extracted for this study [21]. As such, this
study was exempt from Institutional Review Board approval.
2.2 Patient Identification
The study population was commercially insured and Medi-
care Advantage health plan members with PHN initiating
treatment with gabapentin or pregabalin. Patients had one or
more pharmacy claim for either drug during the identifica-
tion period of January 2006 to February 2009; the date of the
first observed pharmacy claim was defined as the index date
and the medication was defined as the index therapy. Patients
were continuously enrolled in the health plans, with medical
and pharmacy benefits, for at least 6 months before the index
date (pre-index period) and 12 months after the index date
(post-index period; included the index date). They had more
than one medical claim with a primary International Clas-
sification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) diagnosis for PHN (053.19) from the start of
the pre-index period through 2 days after index date, and no
claims for the index therapy during the pre-index period [22].
The entire period of observation was 1 July 2005 through 27
February 2010; each patient was observed for 18 months.
2.3 Study Measures
2.3.1 Demographic and Clinical Characteristics
Age, sex and US census region of health plan enrollment
were obtained from enrollment data. A Charlson co-mor-
bidity index score was calculated from ICD-9-CM diag-
nosis codes on medical claims in the pre-index period [23,
24]. Pharmacy claims were examined to identify pre-index
use of non-index medications that could be prescribed for
pain (see Appendix 1, Online Resource).
2.3.2 Dosing Patterns
Index therapy dosing patterns were measured during the
post-index period. All dosing variables were based on
calculations of mean daily dosage. Mean daily dosage for
each index therapy fill was computed as: [(drug
strength 9 quantity dispensed)/days supply]. Mean daily
dosage for each day a patient possessed the index therapy
was recorded; if a patient possessed the index therapy from
more than one prescription fill on any given day, we
assumed that gabapentin or pregabalin were being titrated
and, consequently, the mean daily dosage values associated
with each fill were summed for that day.
‘‘Mean dosage while in possession,’’ was computed as:
[
P
(each day’s mean daily dosage value)/number of days
possessed]; days when patients did not possess index
therapies (i.e., mean daily dosage = 0) were excluded.
‘‘Mean daily dosage excluding gaps of C30 days’’ was
calculated using the equation above but excluding days
when patients did not possess their index therapies if those
days represented a minimum 30-day gap in therapy. Mean
maximum dosage was the highest mean daily dosage value
observed for at least 14 consecutive days; mean maximum
dosage was not computed for patients with fewer than 14
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consecutive days of the same dosage. Time to mean
maximum dosage was the number of days from the index
date to the first day of the mean maximum dosage. Dose
reduction occurred when mean daily dosage dropped from
the mean maximum dosage by C300 mg for gabapentin
and by C150 mg for pregabalin [25, 26].
Patients who received minimally effective dosages of
index therapies were identified. A minimally effective
dosage was defined as an individual fill of the index therapy
with a mean daily dosage of the labeled minimally effective
dosage for PHN (C1,800 mg for gabapentin and C150 mg
for pregabalin) [25, 26]. For pregabalin, an alternative
minimally effective dosage threshold of C300 mg/day was
also examined; this dosage has similar efficacy to the
effective dosage of gabapentin [25, 26]. Patients who did
not have one or more index therapy pharmacy claim with a
minimally effective dosage of either therapy were consid-
ered to have attained sub-therapeutic dosages.
2.3.3 Therapy Outcomes
Discontinuation, persistence, switch from index therapy and
addition of pain medications (other than pregabalin and
gabapentin) to the index therapy were measured during the
post-index period. Discontinuation of index therapy was
defined as a gap in therapy of at least 30 days. The dis-
continuation date was defined by the ‘‘run-out date’’ (i.e.,
fill date ? days supply) of the last index therapy fill prior to
the first observed gap. Discontinuation could occur between
two consecutive therapy fills or between the last observed
index therapy fill and the end of the post-index period.
Persistence was the number of days from the index date to
the discontinuation date. Index therapy switch was defined
as at least one pharmacy claim for a non-index neuropathic
pain medication (Appendix 1, Online Resource) and no
subsequent index therapy fills. The class of medication to
which the patients switched was identified. Neuropathic
pain medication additions were defined as at least one claim
for a condition-specific non-index therapy after the index
date (not including the index therapy), prior to discontinu-
ation of the index therapy, and no fills of the added therapy
during pre-index period (Appendix 1, Online Resource).
2.3.4 Cost and Utilization Outcomes
All-cause healthcare resource utilization and costs were
measured in the pre- and post-index periods. Inpatient
stays, emergency room (ER) visits, outpatient facility vis-
its, and physician office visits were counted per PHN
patient per month. Costs per PHN patient per month were
the sum of health plan and patient-paid amounts and were
adjusted to 2009 US dollars using the Consumer Price
Index [27]. Cost measures included inpatient costs, ER
visit costs, outpatient facility visit costs, physician office
visit costs, other services costs, total medical costs, out-
patient pharmacy costs, and total healthcare (medi-
cal ? pharmacy) costs.
2.4 Analysis
Variables were analysed descriptively. Results were strati-
fied by index therapy cohort and, within cohort, by patients
who received minimally effective and sub-therapeutic index
therapy dosages. T tests were used to identify significant
differences between the means of continuous variables; chi-
squared statistics were used for binary variables.
3 Results
3.1 Dosing Patterns and Therapy Outcomes
A total of 1,645 patients (939 patients receiving gabapentin
and 706 receiving pregabalin) met the study inclusion
criteria (Fig. 1). Pre-index demographic and clinical char-
acteristics are shown in Table 1. Detailed dosing patterns
and therapy outcomes by index therapy cohort are shown in
Table 2. The mean daily dosage excluding any gaps of
30 days was 826 mg for gabapentin and 187 mg for pre-
gabalin. On average, it took patients 30.2 days to reach the
mean maximum dosage of gabapentin (969.5 mg) and
30.3 days to reach the mean maximum dosage of pregab-
alin (221.8 mg). Patients receiving gabapentin or pregab-
alin remained on the therapy for an average of 72.9 and
79.5 days, respectively (p = 0.160). Patients treated with
gabapentin (10 %) were more likely to have their dosages
reduced than were patients receiving pregabalin (4 %,
p \ 0.001).
The mean daily dosages for the first fills of gabapentin
or pregabalin were 760 mg and 175 mg, respectively
(Appendix 2, Online Resource). Only slightly more than
half of all patients had more than one fill of their index
therapies (Fig. 2). Patients treated with gabapentin
appeared to experience upward dosage titration through the
first five fills of therapy, whereas patients treated with
pregabalin appeared to be titrated upward for the first six to
seven fills of therapy based on the mean dosage. Over half
of patients switched from their index therapies during the
post-index period (Fig. 3; Table 2). Of those who switched,
approximately one-third switched to opioids (gabapentin,
35 %; pregabalin, 31 %; p = 0.258; Fig. 4a). Additionally,
37 % of patients in the gabapentin cohort and 31 % of
patients in the pregabalin cohort added medication to their
index therapies (Table 2); opioids were added by 57 % of
patients taking gabapentin and 58 % of patients taking
pregabalin (Fig. 4b).
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3.2 Dosing Patterns and Therapy Outcomes of Patients
Receiving Minimally Effective and Sub-
therapeutic Dosages of Therapy
Only 134 (14 %) patients taking gabapentin received at
least one fill of the minimally effective dosage (C1,800 mg/
day) and the mean time to reach this dosage was about
10 weeks (Table 3). In contrast, 611 (87 %) of patients
taking pregabalin received at least one fill of the minimally
effective dosage of C150 mg/day and 194 (27 %) had at
least one fill at C300 mg/day. The mean times to reach
daily dosages of C150 mg or C300 mg of pregabalin were
about 5 weeks and 9.2 weeks, respectively. Patients
receiving sub-therapeutic dosages of gabapentin or pre-
gabalin were more likely than those who had received a
minimally effective dosage to be switched to antidepres-
sants (data not shown; 0.2 % minimally effective, 3 % sub-
therapeutic; p = 0.004) or opioids (data not shown; 27 %
minimally effective, 38 % sub-therapeutic; p \ 0.001).
Patients treated with sub-therapeutic dosages of gaba-
pentin (94 %) were more likely to have gaps in therapy
than were those receiving minimally effective dosages
(87 %, p = 0.002; Table 4). The mean total days on index
therapy and mean total number of fills for index therapy
were significantly higher for patients treated with mini-
mally effective dosages of gabapentin compared to those
treated with sub-therapeutic dosages (all p \ 0.001). The
mean total days on index therapy (p = 0.001) and mean
total number of fills for index therapy (p \ 0.001) were
also significantly higher for patients treated with minimally
effective dosages of pregabalin (C150 mg/day) compared
with those treated with lower dosages.
3.3 Healthcare Resource Use and Cost
There were no differences in healthcare utilization between
patients who were going to receive gabapentin or pregabalin
in the pre-index period with the exception of the mean count
of all-cause inpatient admissions, which were higher in
patients receiving gabapentin compared with patients
receiving pregabalin (p = 0.012; Table 5). In the post-index
period, patients receiving gabapentin had significantly
Fig. 1 Sample selection and attrition
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higher mean all-cause monthly office visit counts than did
patients receiving pregabalin (p = 0.033). The gabapentin
cohort had higher mean office visit costs per month com-
pared with the pregabalin cohort in the post-index period
(p = 0.048). However, patients receiving pregabalin had
significantly higher mean all-cause pharmacy costs than did
patients receiving gabapentin (p \ 0.001). The mean all-
cause total healthcare costs per month were US $1,136 and
US $1,007 in the pre-index period for the gabapentin and
pregabalin cohorts, respectively (p = 0.244) and US $1,749
and US $1,570 in the post-index period for the gabapentin
and pregabalin cohorts, respectively (p = 0.512, Table 5).
4 Discussion
This retrospective administrative claims data-based study
was undertaken to better understand the dosing patterns,
therapy outcomes, and healthcare utilization and costs for
patients with PHN who initiated treatment with gabapentin
or pregabalin.
Prior studies have indicated that gabapentin can be
initiated at 900 mg/day for treatment of neuropathic pain,
and that additional titration to 1,800 mg/day is often
necessary for full efficacy [28, 29]. However, dosages of
up to 3,600 mg/day may be required in some patients [28,
29]. The recommended duration for gabapentin titration
for PHN is 3–8 weeks [30]. Our study found that the
mean daily dosage and average maximum dosage for
patients receiving gabapentin were 826 and 969 mg,
respectively, which both were lower than the labeled
dosage of 1,800 mg. Only 14 % of the patients receiving
gabapentin were titrated to the minimally effective dosage
of 1,800 mg or higher; the average maximum dosage for
them was 2,224 mg and it took approximately 10 weeks
to reach this level. Patients who received the minimally
effective dosage of gabapentin remained on therapy for an
average of 17 weeks.
The recommended dosage of pregabalin for PHN is
150–300 mg daily [30, 31]. If pain relief is inadequate
following 2–4 weeks of pregabalin at 300 mg/day, the
dosage may be increased to 600 mg daily [13]. In our
study, the mean daily dosage for patients taking pregab-
alin was 187 mg, the mean maximum dosage was
222 mg, and it took 30 days on average to reach the
maximal level. Approximately 87 % of patients achieved
Table 1 Demographic and
clinical characteristics by index
therapy cohorta
NS not significant
a Values are n (%) except
where otherwise stated
b All 2-way continuous
comparisons between
gabapentin and pregabalin index
therapy cohorts were performed
using t tests; comparisons of
binary variables between








Age, years (mean ± SD)c 63.82 ± 15.01 61.99 ± 14.61 0.014
Age, years
18–44 105 (11.18) 83 (11.76) NS
45–64 380 (40.47) 334 (47.31) 0.006
C65 454 (48.35) 289 (40.93) 0.003
Sex
Male 368 (39.19) 299 (42.35) NS
Female 571 (60.81) 407 (57.65) NS
Insurance type
Commercial 693 (73.80) 583 (82.58) \0.001
Medicare advantage 246 (26.20) 123 (17.42) \0.001
Region
Northeast 88 (9.37) 57 (8.07) NS
Midwest 338 (36.00) 182 (25.78) \0.001
South 370 (39.40) 369 (52.27) \0.001
West 143 (15.23) 98 (13.88) NS
Quan-Charlson co-morbidity score
(mean ± SD)c
1.05 ± 1.58 0.90 ± 1.36 0.040
Quan-Charlson co-morbidity score
0 495 (52.72) 383 (54.25) NS
1 204 (21.73) 165 (23.37) NS
2 111 (11.82) 83 (11.76) NS
3 54 (5.75) 40 (5.67) NS
4 35 (3.73) 17 (2.41) NS
C5 40 (4.26) 18 (2.55) NS
Pre-index opioid use 646 (68.80) 504 (71.39) NS
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dosages of pregabalin C150 mg/day, but only 27 % of
patients received dosages of pregabalin C300 mg/day.
The mean maximum dosage of patients receiving
150 mg/day was 243 mg and the average time to reach
this maximum dosage was 33 days. Patients who
received the minimally effective dosage of pregabalin
(C150 mg/day) remained on therapy for an average of
12 weeks.
Table 2 Dosing patterns and therapy outcomes by index therapy cohort
Variable Gabapentin (n = 939)a Pregabalin (n = 706)a P valueb
Daily dose excluding any gaps of 30 days, mg (mean ± SD) 826.26 ± 559.27 187.08 ± 102.88 –
Daily dose while in possession, mg (mean ± SD)c 875.12 ± 602.41 199.51 ± 109.68 –
Time to maximum dose days (mean ± SD)d 30.24 ± 70.70e 30.26 ± 70.63f –
Maximum dose, mg (mean ± SD)d 969.52 ± 737.66e 221.83 ± 146.55f –
Time on index therapy, days (mean ± SD)g 72.87 ± 93.52 79.51 ± 96.53 NS
Number of fills for index therapy (mean ± SD)h 3.08 ± 3.18 3.30 ± 3.37 NS
Reduction in dose of index therapy during post-index period [n (%)]d 87 (9.93)e 29 (4.39)f \0.001
Gap in therapy [n (%)] 877 (93.40) 661 (93.63) NS
Switch from index therapy [n (%)] 544 (57.93) 394 (55.81) NS
Added to index therapy [n (%)] 348 (37.06) 218 (30.88) 0.009
NS not significant; – signifies statistical analyses not performed
a Number of patients used for statistical calculation except where otherwise stated
b T tests were used to identify significant differences between the means of continuous variables; chi-squared statistics were used for binary
variables
c Dose while in possession was the daily dose only on those days that the patient had the index drug (e.g. excluded all gap days, included gaps
fewer than 30 days)
d For patients with C14 days on one maximum dose
e 876 patients
f 661 patients
g Number of days prior to evidence of gap or switch from index medication
h Throughout the entire follow-up period
Fig. 2 Number of index
therapy fills
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Our data illustrate that many patients with PHN do not
achieve the minimally effective dosage of gabapentin
(1,800 mg/day) or pregabalin at dosage levels (C300 mg/
day) with similar efficacy to the minimally effective dosage
of gabapentin. This may have been due to several patient
factors including co-morbidities, polypharmacy or issues
with tolerability that would make it clinically unfeasible for a
patient to reach a minimally effective dosage. Additionally,
providers’ clinical judgements about patients’ analgesic
responses at less than the labeled dosing levels, or without
titration, may also be a factor when prescribing these
therapies. Adverse events may be a contributing factor to
why patients may not have achieved the minimally effective
dosage following treatment initiation. Prior studies have
shown that adverse events are a principal reason why people
stop taking gabapentin or pregabalin [32]. However, some
patients may have discontinued their medication rather than
escalating to minimally effective dosage levels because they
were not achieving sufficient pain management.
Half of the patients who took gabapentin or pregabalin in
our study did not fill more than one prescription, and over
half of the patients switched therapies. Of the patients who
switched, one-third switched to opioids. A study by Gore
et al. [33] focused specifically on the dosages prescribed in
clinical practice and changes in the use of other neuropathic
pain-related medications after the initiation of gabapentin or
pregabalin and found similar results. In this study, patients
with PHN increased opioid use after the initiation of
gabapentin and decreased opioid use after the initiation of
pregabalin. As in our study, more patients received a min-
imally effective dosage of pregabalin (69 %, C150 mg/day)
than they did gabapentin (14 %, C1,800 mg/day); however,
our study found that a higher proportion of pregabalin
patients added an opioid after treatment initiation than did
those receiving gabapentin. Gore et al. [33] study also found
that patients treated with pregabalin were more likely to
attain therapeutic dosage levels earlier than were those
patients who were prescribed gabapentin.
Our study was subject to certain limitations. The data
used for this study come from a managed-care population
and therefore the results may not be applicable to patients
who are uninsured or underinsured. In addition, there are
inherent limitations with the use of administrative claims
data. First, some clinical and disease-specific parameters
that might affect choice of treatment and study outcomes
(e.g., adverse events, pain severity) are not available in
claims data. Second, the presence of a diagnosis code on
a medical claim is not a positive identification of a dis-
ease, as the diagnosis code may be incorrectly coded or
codes may not precisely capture the diagnosis of interest
or extent of disease. However, our analysis required a
primary diagnosis that may have mitigated the likelihood
of misclassification. Third, it is not possible to determine
whether patients use medications as prescribed. Also,
estimates of healthcare utilization and costs provided are
all-cause, not PHN-specific. Lastly, in this study, opioids
may have been used for other pain-related co-morbidities
and it is possible that some patients did not reach optimal
dosages because of side effects due to polypharmacy;
these were not examined.
Current guidelines for pharmacological treatment of
neuropathic pain are based on the results of randomized
clinical trials and may not reflect ‘‘real-world’’ patterns of
use in usual-care settings. Our results indicate that
Fig. 3 Patients who added to or switched from index therapy
Fig. 4 Classes of medications a to which patients switched or b that
were added to index therapy. TCA tricyclic antidepressants
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gabapentin and pregabalin are not being used effectively
for the treatment of PHN. Sub-optimal dosing may lead to
inadequate treatment response, which can in turn lead to
early discontinuation of therapy, to switching to second-
line therapies for PHN, or to addition of other analgesics.
Taken together, these factors could possibly lead to
unnecessarily high use of opioids which are currently ‘‘at
the center of a major public health crisis of addiction,
misuse, abuse, overdose and death’’ [34–36].
5 Conclusion
These findings show that many patients with PHN do not
achieve the minimally effective dosages of gabapentin or
pregabalin. The study also highlights possible issues with
titration, the attainment of optimal dosages, and the toler-
ability of therapy in clinical practice. Further tolerability
studies are warranted in studies of the pharmacological
treatment of PHN.
Table 3 Dosing patterns and therapy outcomes in patients receiving minimally effective doses of index therapya, b






Daily dose excluding any gaps of 30 days (mg) 1710.87 ± 836.42 203.15 ± 101.16 310.66 ± 116.15
Daily dose while in possession (mg)d 1892.38 ± 851.85 217.06 ± 107.41 335.43 ± 118.52
Time to maximum dose (days)e 68.94 ± 89.26f 33.18 ± 73.01g 64.54 ± 95.26h
Maximum dose (mg)e 2224.24 ± 1,007.34f 242.68 ± 146.90g 396.85 ± 168.19h
Reduction in dose of index therapy during post-
index period [n (%)]e
35 (27.78)f 29 (5.08)g 27 (14.59)h
a Minimally effective doses were defined as C1800 mg/day of gabapentin and C150 mg/day of pregabalin. Sub-therapeutic doses were defined
as less than the minimally effective daily dose
b Values are mean ± SD except where otherwise stated
c Number of patients used for statistical calculation except where otherwise stated
d Dose while in possession was the daily dose only on those days that the patient had the index drug (e.g. excluded all gap days, included gaps
fewer than 30 days)















Gap in therapy [n (%)] 117 (87.31) 760 (94.41) 0.002 568 (92.96) 93 (97.89) NS
Switch from index therapy [n
(%)]
68 (50.75) 476 (59.13) NS 341 (55.81) 53 (55.79) NS
Time on index therapy, days
(mean ± SD)c
119.89 ± 109.21 65.04 ± 88.32 \0.001 83.06 ± 99.95 56.71 ± 66.74 0.001
Number or fills for index therapy
(mean ± SD)d
5.15 ± 3.44 2.74 ± 3.00 \0.001 3.47 ± 3.47 2.24 ± 2.47 \0.001
NS not significant
a Minimally effective doses were defined as C1800 mg/day of gabapentin and C150 mg/day of pregabalin. Sub-therapeutic doses were defined
as less than the minimally effective daily dose
b Sub-therapeutic versus minimally effective dose within index therapy cohorts. All 2-way continuous comparisons between gabapentin and
pregabalin index therapy cohorts were performed using t tests; comparisons of binary variables were evaluated with chi-squared statistics
c Number of days prior to evidence of gap or switch from index medication
d Throughout the entire follow-up period
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